Genome Research Group Issues Corporate Update and Outlines Objectives
02 Settembre 2010 - 2:30PM
Marketwired
Genome Research Group (GRG) (PINKSHEETS: KKUR) recently announced
its intended merger with ChromoCure, Inc. and consolidation of the
operations and technologies of both groups. Genome Research Group
personnel have assumed all executive and board duties and have no
current or planned operations in the USA.
The company intends to open permanent offices in the United
Kingdom as well as establish the first of several planned research
labs and testing partners.
To date, the Company has not been able to secure its previously
anticipated investment capital due to the declining USA economy and
capital markets. The Company believes it has now secured
satisfactory capital commitments and will proceed with its business
plan accordingly.
The Company's objectives are:
1. Recapitalize the company's stock structure and change the company's
trading symbol to trade under "Genome Research Group."
2. Establish business offices and permanent address in the United Kingdom
with the most likely location being London.
3. Structure the company's operations as decentralized management with
multiple operational hubs and team members around the world.
4. Secure initial research lab space for the Company's ongoing research and
development for both its cancer imaging systems as well as its
therapeutic protocols and animal modeling experiments.
5. Appoint industry leaders to the Company's Board of Advisors.
6. Partner with cancer labs and pathology labs within the European Union.
The Company does not believe the USA healthcare market will be an open
market inviting of innovation or new ideas. The Company has no immediate
plans to seek partnerships within the USA due to healthcare over-
regulation and control by the US government.
7. Complete and deploy company branding, image, and professional design of
marketing and educational materials.
8. File updated financial information with appropriate legal opinion letter
to achieve "Current" reporting status. The Company has no immediate
intent to become a "SEC Reporting" company due to the massive expense
and liability of that status.
The Company intends to release updates from time to time as
these actions are completed.
About Genome Research Group Genome
Research Group develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary cancer detection system locates and measures unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's proprietary Therapeutic Modeling
Protocols provide statistical modeling and prediction tools for the
measurement and monitoring of cancer progression and remission. GRG
owns proprietary techniques for non-toxic and non-invasive cancer
therapy utilizing hypothermic modulation and resonance.
Safe-Harbor Statement This release may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements
contained in this release that are not historical facts may be
deemed to be forward-looking statements. Investors are cautioned
that forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected
or suggested herein due to certain risks and uncertainties
including, without limitation, ability to obtain financing and
regulatory and shareholder approvals for anticipated actions.
Genome Research Group, Inc. www.genomeresearchgroup.com
info@genomeresearchgroup.com Tel: +011 (44) 20 7101 9475
Grafico Azioni Chromocure (CE) (USOTC:KKUR)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Chromocure (CE) (USOTC:KKUR)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a Chromocure Inc (CE) (OTCMarkets): 0 articoli recenti
Più Genome Research Group Articoli Notizie